Literature DB >> 11310814

Acute and maintenance treatment of chronic depression.

D L Dunner1.   

Abstract

Chronic forms of depression account for approximately one third of all depressions. They are underrecognized and undertreated. This article defines the types of chronic depressions (dysthymic disorder, double depression, chronic major depression, and major depression in incomplete remission). A review of treatments for patients with these conditions is provided. The basic principles of treatment of chronic depression involve longer treatment and higher doses than are usually required for acute major depression. The impact of psychosocial disability and severity of depressive symptoms can be ameliorated with appropriate treatment. Newer treatments, such as the combination of psychotherapy and pharmacotherapy, may prove to be of greatest benefit for individuals with chronic mood disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11310814

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  [A specific therapy for chronic depression. McCullough's Cognitive Behavioral Analysis System of Psychotherapy].

Authors:  E Schramm; F Caspar; M Berger
Journal:  Nervenarzt       Date:  2006-03       Impact factor: 1.214

Review 2.  Antidepressant drug effects and depression severity: a patient-level meta-analysis.

Authors:  Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Sona Dimidjian; Jay D Amsterdam; Richard C Shelton; Jan Fawcett
Journal:  JAMA       Date:  2010-01-06       Impact factor: 56.272

Review 3.  [Affective disorders. The significance of psychotherapeutic approaches].

Authors:  M Berger; E L Brakemeier; C Klesse; E Schramm
Journal:  Nervenarzt       Date:  2009-05       Impact factor: 1.214

4.  [Guideline-conform inpatient psychiatric psychotherapeutic treatment of chronic depression: Normative personnel requirements].

Authors:  K Schnell; A Hochlehnert; M Berger; J Wolff; M Radtke; E Schramm; C Normann; S C Herpertz
Journal:  Nervenarzt       Date:  2016-03       Impact factor: 1.214

5.  Discontinuation of antidepressants during attempts to conceive: a pilot trial of cognitive behavioral therapy for the prevention of recurrent depression.

Authors:  Christina Psaros; Marlene Freeman; Steven A Safren; Maria Barsky; Lee S Cohen
Journal:  J Clin Psychopharmacol       Date:  2014-08       Impact factor: 3.153

Review 6.  Diagnosis and treatment of dysthymia in children and adolescents.

Authors:  Maria Nobile; Giulia M Cataldo; Cecilia Marino; Massimo Molteni
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study.

Authors:  Christian A Webb; Madhukar H Trivedi; Zachary D Cohen; Daniel G Dillon; Jay C Fournier; Franziska Goer; Maurizio Fava; Patrick J McGrath; Myrna Weissman; Ramin Parsey; Phil Adams; Joseph M Trombello; Crystal Cooper; Patricia Deldin; Maria A Oquendo; Melvin G McInnis; Quentin Huys; Gerard Bruder; Benji T Kurian; Manish Jha; Robert J DeRubeis; Diego A Pizzagalli
Journal:  Psychol Med       Date:  2018-07-02       Impact factor: 7.723

8.  Chronic depression: development and evaluation of the luebeck questionnaire for recording preoperational thinking (LQPT).

Authors:  Tanja Kühnen; Franziska Knappke; Tanja Otto; Stephanie Friedrich; Jan P Klein; Kai G Kahl; Michael Hüppe; Valerija Sipos; Ulrich Schweiger
Journal:  BMC Psychiatry       Date:  2011-12-20       Impact factor: 3.630

Review 9.  The effectiveness of individual interpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a systematic review.

Authors:  Madelon L J M van Hees; Thomas Rotter; Tim Ellermann; Silvia M A A Evers
Journal:  BMC Psychiatry       Date:  2013-01-11       Impact factor: 3.630

10.  The effect of oxytocin on attention to angry and happy faces in chronic depression.

Authors:  Gregor Domes; Claus Normann; Markus Heinrichs
Journal:  BMC Psychiatry       Date:  2016-04-06       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.